Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
about
Hypoplastic left heart syndrome: current considerations and expectationsImmunologic considerations in heart transplantation for congenital heart diseaseOutcomes of cardiac transplantation in highly sensitized pediatric patientsBortezomib use in a pediatric cardiac transplant center.Pediatric heart transplantation-indications and outcomes in the current era.Impact of ABO-incompatible listing on wait-list outcomes among infants listed for heart transplantation in the United States: a propensity analysis.Outcomes after listing with a requirement for a prospective crossmatch in pediatric heart transplantation.Comparison of listing strategies for allosensitized heart transplant candidates requiring transplant at high urgency: a decision model analysis.The long-term outcome of treated sensitized patients who undergo heart transplantation.Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.Assessment and management of the failing heart in children.Report from a consensus conference on the sensitized patient awaiting heart transplantationChallenges with sensitized recipients in pediatric heart transplantation.Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.Heart transplantation in adults with end-stage congenital heart disease.Cardiac antibody-mediated rejection.Heart transplant after the Fontan operation.B-type natriuretic peptide trends after pediatric heart transplantation.Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute.Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine.Results of heart transplantation following failed staged palliation of hypoplastic left heart syndrome and related single ventricle anomalies.Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patientsDonor-specific antibodies: can they predict C4d deposition in pediatric heart recipients?Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.Charges and resource utilization for pediatric heart transplantation across a positive virtual and/or cytotoxicity crossmatch.Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner.Clinical significance of anti-HLA antibodies associated with ventricular assist device use in pediatric patients: A United Network for Organ Sharing database analysis.Study Rationale, Design and Pre-Transplant Alloantibody Status: A First Report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in Pediatric Heart Transplantation.
P2860
Q26821904-89831A0D-5D1D-48D5-8A13-8B3DCE8A9B24Q26995790-3A8FDB40-81A1-4B13-A0D7-BACAAF4345F2Q28744582-786D70EA-83CD-42B4-A342-B4E069CE61E3Q33415926-9922D766-8784-4B89-A5C3-3A3D7A5C74A3Q34048053-214157BA-B65C-45DD-A852-4CA12656741CQ34110960-780642A4-50E3-4F12-BD1B-48F27C8F4328Q36702162-918BF5D4-5FC8-41C5-9F89-3614563A4A07Q36956131-788658E9-3B7A-4DD4-9F48-9DA4CA8CCD9CQ37313073-2E5DBD45-1B49-4561-8A73-66B5A5149FB1Q37350033-CD1EB2FC-82E5-4C13-B7BD-DA82E1EF0E99Q37354328-BF525A2A-42A3-4705-B364-9632980F8B8EQ37414657-CBA397DE-3170-4B74-9D5A-88AA081E1DD8Q37446864-257875E1-0D9B-409A-8D6B-9510C2E1096CQ37966118-07480E8E-1123-4C7A-99BD-5120D2740088Q37993155-C6137C64-D78D-4009-A779-A68E7AC72C32Q38002449-7F0CD58D-CAE3-45CC-A891-E35F3F6A86ABQ38176692-24760A4E-E339-4CB8-BBDA-BB0AC92FB97AQ38219702-B68F5306-F33C-49CF-8EE2-31934D5C6485Q38588150-E3F2B00F-6DF4-4A3E-96FD-739329BF56D1Q38588170-0214D31B-4C67-4A48-BA4E-50BAD78FA150Q41559290-527DE7DA-CE69-4D30-B785-03BD285BC333Q42656427-2CD7406B-B224-45C7-A0D1-27A3C46B5AFEQ44055243-23414277-0F72-45FE-B100-1E920106CD9BQ45821566-EA19EAF7-CF22-4E3F-835B-7255D9608652Q47293101-A2A9DCAD-FD76-4793-AE82-C482FD39B7F4Q48112929-635858F3-8F79-4C1B-9F66-15388CF579E1Q48346184-A304FAB4-6CEC-4B69-932B-D6D188768992Q49989953-DFC5EEE4-E725-4B63-8132-DF0C6A1522D3
P2860
Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mortality and morbidity in pre ...... heresis and cytolytic therapy.
@en
type
label
Mortality and morbidity in pre ...... heresis and cytolytic therapy.
@en
prefLabel
Mortality and morbidity in pre ...... heresis and cytolytic therapy.
@en
P2093
P1476
Mortality and morbidity in pre ...... pheresis and cytolytic therapy
@en
P2093
Charles B Huddleston
Charles E Canter
D Byron Holt
Donna L Phelan
Douglas M Lublin
Jeffrey E Saffitz
Sarah E Boslaugh
P304
P356
10.1016/J.HEALUN.2007.07.011
P577
2007-09-01T00:00:00Z